10

Loading video...

Melissa Fleur Afshar

By Melissa Fleur Afshar

Reporter

0

Share

Newsweek is a Trust Project member

See more of our trusted coverage when you search.Prefer Newsweek on Googleto see more of our trusted coverage when you search.


APOE4, a high-risk gene frequently mulled over by dementia experts, and one that instantly rings alarm bells as a huge genetic predictor for Alzheimer's disease, could one day be eradicated.

Scientists at England's University of Bristol have developed a groundbreaking new gene therapy that converts APOE4 into the lower-risk APOE3 gene. While it is still early days—the team first set their sights on the breakthrough in 2024—the researchers are ambitious, and hope to one day make serious inroads in finding one of the most efficient treatments to date for the disease that destroys millions of lives every year.

Newsweek spoke to Dr. Kevin Kemp, an associate professor at Bristol's school of psychology and neuroscience, who co-led the study, to get up to speed with the breakthrough.

Read More on Science

Deciding To Rewrite Alzheimer’s Risk

The team's motivation to pursue research rested on two questions; rather than simply trying to manage the consequences of Alzheimer's, could they rewrite its biggest genetic risk factor? And could genetic engineering lead to harmful changes in the surrounding cells' DNA? The latter is what had held back prior research efforts.

Triumphantly, Kemp and his team have now demonstrated in human immune cells that APOE4 can be converted to APOE3, with little impact on surrounding cells' DNA. The work remains experimental, but it offers an early glimpse into how gene editing might eventually be used to prevent or slow Alzheimer's in some of those at greatest perceived risk.

Late-onset Alzheimer's, experienced by people in their late 60s, 70s and 80s, accounts for most Alzheimer's cases. There is no single known cause, but lifestyle, environmental and genetic factors can influence someone's risk. Among those genes, APOE4 commands particular attention among neurologists.

Everybody carries two copies of the APOE gene, one inherited from each parent. Its common variants include APOE2, associated with lower dementia risk; APOE3, the most common, and regarded as neutral; and APOE4, the highest-risk variant.

Around one in four people carry APOE4.

"People who have two copies of the APOE4 gene are around eight to 12 times more likely to develop Alzheimer's in later life than those who carry two copies of APOE3," Kemp told Newsweek, from the university.

Dr. Kevin Kemp works in a laboratory at University of Bristol in England.

...

Yet it is precisely these genetic differences that presented the researchers with an opportunity to investigate further. The common APOE variants differ by only small changes in the DNA code, raising the prospect of deliberately editing the high-risk version into a lower-risk one.

The project grew from a one-year pilot study funded by Bristol-based charity BRACE Dementia Research. Kemp said the team applied for funding in 2024, with work beginning by early 2025.

He is also quick to distribute credit to other members of the team, predominantly Dr. Abigail Harland, a research associate in gene therapy.

Recoding a Major Risk Factor

APOE carries instructions for apolipoprotein, a protein involved in transporting lipids and cholesterol to cells in the brain. Those lipids are important for nerve-cell health, immune function, and the clearance of toxic proteins.

Understandably, APOE4 is less efficient at performing these jobs, potentially affecting cell health while leaving cells vulnerable to the toxic proteins associated with cognitive decline.

The Bristol team's ambition is therefore to change the underlying genetic code.

Using human immune blood cells derived from people with Alzheimer's who carried two copies of APOE4, researchers successfully converted the high-risk gene into APOE3.

"We can use engineered enzymes to make precise chemical changes to DNA, enabling us to convert APOE4 into APOE3," Kemp said.

Crucially, the team also wanted to know whether intervening in one place could unintentionally disturb DNA elsewhere, a longstanding safety concern surrounding genetic engineering.

"Quite excitingly, using this technique, we've been able to show that there are minimal changes elsewhere in the APOE gene," Kemp said.

Inside the Laboratory

The researchers used engineered enzymes to target precise parts of the sequence of the genetic code, to pinpoint the exact code that encodes the APOE gene. From there, DNA was chemically altered to convert APOE4 to its lower-risk counterpart.

"So, we've been doing this in the lab, and we've been able to obtain immune cells from people who carry two copies of APOE4," Kemp added.

Working with human immune cells enabled the researchers to examine responses closer to those expected in people than some earlier-stage laboratory models might allow.

For Kemp, watching genetic engineering cease to be an abstraction remains one of the most extraordinary parts of the project.

"I still have to pinch myself thinking that we can make positive changes to DNA that could help patients in the future," he said.

The Next Stage of Development

Despite the early triumph, editing cells in a dish was only the team's first challenge to coveting a real therapy. The machinery they have developed must ultimately reach the human brain safely and effectively.

The team has packaged its gene-editing machinery into a modified virus designed to potentially be injected into the bloodstream. The virus would target immune cells, converting APOE4 to APOE3. Those cells could then travel into the brain and produce therapeutic APOE3 protein that can then cross correct other nerve cells in the brain.

The approach is designed to help bypass the blood-brain barrier.

Researchers will now test the delivery system in different models, studying whether edited cells function better and become efficient at clearing toxic proteins. It is here that the distance between a promising experiment and a treatment becomes clearest.

The team must establish that the editing works efficiently and safely inside the body while also investigating the entire genome for unintended changes. Gene therapies face stringent safety requirements before reaching clinical trials; Kemp estimates first-in-human testing could still be five to 10 years away.

But the potential need remains significant. Some disease-modifying Alzheimer's therapies can slow progression, but people carrying two copies of APOE4 can be excluded from certain treatments because of risks including brain swelling.

Kemp nevertheless cautions against interpreting genetics as destiny. Even two copies of APOE4 do not mean somebody will inevitably develop Alzheimer's. Healthy lifestyles, cerebral pursuits and social connections can also help reduce risk, he said.

Still, he believes gene therapies targeting APOE4 could eventually alter the treatment landscape.

"I really do," he said when asked whether this work could ultimately produce a meaningful treatment. "I think it's critically important that we develop effective treatments for people who carry the APOE4 gene."

Contact Newsweek editors on this story: Kara Dolman and Paul Donnelley.

View 0 Comments

Request Reprint & Licensing

Submit Correction

View Editorial & AI Guidelines